Company Overview of Shantha Biotechnics Limited
Shantha Biotechnics Limited, a biotechnology company, researches, develops, manufactures, markets, and sells vaccines. The company offers human vaccines against hepatitis B, tetanus, diphtheria, pertussis, haemophilus influenza type B conjugate, and cholera, as well as recombinant erythropoietin. It serves customers in India and internationally. The company was founded in 1993 and is based in Hyderabad, India. Shantha Biotechnics Limited operates as a subsidiary of Sanofi Pasteur SA. As per the transaction announced on September 30, 2015, Shantha Biotechnics Limited has been acquired by Sanofi (ENXTPA:SAN).
3rd & 4th Floor
Fateh Maidan Road
Founded in 1993
Key Executives for Shantha Biotechnics Limited
Chief Executive Officer, Managing Director, Dierctor, Member of Share Transfer Committee and Member of Audit Committee
Founder, Chairman, Member of Share Transfer Committee, Member of Audit Committee and Member of Remuneration Committee
Chief Financial Officer and Company Secretary
Director, Member of Remuneration Committee, Chief Executive Officer of Sanofi Pasteur and President of Sanofi Pasteur
Head of Research and Development
Compensation as of Fiscal Year 2015.
Shantha Biotechnics Limited Key Developments
Sanofi Pasteur Announces Availability of ShanIPV Manufactured by Shantha Biotechnics
Dec 29 15
Sanofi Pasteur has announced the availability of ShanIPV, a new injectable, inactivated polio vaccine, or IPV, manufactured by its affiliate, Shantha Biotechnics, in Hyderabad, India. These first vaccine doses will be available to implement one dose of IPV in India's immunization schedule for all infants. Sanofi Pasteur and its affiliate Shantha Biotechnics will together produce most of India's IPV supply.
Shantha to Establish New Insulin Manufacturing Facility in India
Feb 2 15
Sanofi SA (France) subsidiary Shantha Biotechnics (India) announced on 29 January that it will be establishing a new insulin-production site in Telangana, India. The new facility will serve to manufacture Sanofi's human insulin product Insuman (recombinant human insulin). Sanofi has pledged an investment of INR 4.6 billion (USD 85.19 million) towards the facility and expects an annual production rate of 60 million Insuman cartridges in the first 2-3 years.
Shantha Launches Paediatric Pentavalent Vaccine, Shan5
Nov 10 14
Sanofi Pasteur launched Shan5, its paediatric pentavalent vaccine developed and manufactured by its Indian affiliate Shantha. It is a fully-liquid five-in-one vaccine that provides effective protection for children from six weeks of age against five diseases, diphtheria, tetanus, pertussis, Hib and hepatitis B. The launch of Shan5 vaccine received prequalification status from the World Health Organization (WHO) in April 2014. Shan5’s prequalification gives many more children in India access to the latest fully-liquid, 5-in-1 vaccine. Further, the prequalification helps Shan5 secure the supply of pentavalent combination vaccines in over 50 emerging and low-income countries.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|